Verification of a cocktail approach for quantitative drug–drug interaction assessment: a comparative analysis between the results of a single drug and a cocktail drug

References

• Arnold, Y.E., et al., 2019. Drug transport across porcine intestine using an using chamber system: regional differences and the effect of P-glycoprotein and CYP3A4 activity on drug absorption. Pharmaceutics, 11 (3), 139.
   Web of Science ®Google Scholar
• Backman, J.T., et al., 1998. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. European journal of clinical pharmacology, 54 (1), 53–58.
   PubMed Web of Science ®Google Scholar
• Backman, J.T., Olkkola, K.T., and Neuvonen, P.J., 1996. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clinical pharmacology & therapeutics, 59 (1), 7–13.
   PubMed Web of Science ®Google Scholar
• Christensen, M., et al., 2003. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clinical pharmacology and therapeutics, 73 (6), 517–528.
   PubMed Web of Science ®Google Scholar
• Chung, E. Jr., et al., 2006. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clinical pharmacology & therapeutics, 79 (4), 350–361.
   PubMed Web of Science ®Google Scholar
• Collado-Borrell, R., et al., 2016. Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account. Journal of cancer research and clinical oncology, 142 (11), 2319–2330.
   PubMed Web of Science ®Google Scholar
• Derayea, S.M., et al., 2019. Investigation on drug-binding in heme pocket of CYP2C19 with UV-visible and resonance Raman spectroscopies. Spectrochimica acta. Part A, molecular and biomolecular spectroscopy, 209, 209–216.
   PubMed Web of Science ®Google Scholar
• Desta, Z., Kerbusch, T., and Flockhart, D.A., 1999. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clinical pharmacology and therapeutics, 65 (1), 10–20.
   PubMed Web of Science ®Google Scholar
• Di Minno, A., et al., 2017. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood reviews, 31 (4), 193–203.
   PubMed Web of Science ®Google Scholar
• Dooley, K.E., et al., 2012. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clinical pharmacology & therapeutics, 91 (5), 881–888.
   PubMed Web of Science ®Google Scholar
• Dresser, G.K., Spence, J.D., and Bailey, D.G., 2000. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clinical pharmacokinetics, 38 (1), 41–57.
   PubMed Web of Science ®Google Scholar
• Elliott, P., et al., 1984. The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam. European journal of anaesthesiology, 1 (3), 245–251.
   PubMedGoogle Scholar
• European Medicines Agency, (2015). Guideline on the investigation of drug interactions. Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf [Accessed 14 April 2020].
   Google Scholar
• Fee, J.P., et al., 1987. Cimetidine and ranitidine increase midazolam bioavailability. Clinical pharmacology and therapeutics, 41 (1), 80–84.
   PubMed Web of Science ®Google Scholar
• Frye, R.F., et al., 1997. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clinical pharmacology and therapeutics, 62 (4), 365–376.
   PubMed Web of Science ®Google Scholar
• Goldberg, M.R., et al., 1995. Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. European journal of clinical pharmacology, 49 (1-2), 115–119.
   PubMed Web of Science ®Google Scholar
• Gorski, J.C., et al., 2003. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clinical pharmacology & therapeutics, 74 (3), 275–287.
   PubMed Web of Science ®Google Scholar
• Greenblatt, D.J., et al., 1986. Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. Anesthesia and analgesia, 65 (2), 176–180.
   PubMed Web of Science ®Google Scholar
• Inui, N., et al., 2013. Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method. Clinical pharmacology and therapeutics, 94 (6), 702–708.
   PubMed Web of Science ®Google Scholar
• Ishizaki, T., et al., 1987. Evidence for polymorphic oxidation of sparteine in Japanese subjects. British journal of clinical pharmacology, 23 (4), 482–485.
   PubMed Web of Science ®Google Scholar
• Kamiya, C., et al., 2019. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. Journal of pharmacological sciences, 139 (4), 361–366.
   PubMed Web of Science ®Google Scholar
• Kasichayanula, S., et al., 2014. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. British journal of clinical pharmacology, 78 (5), 1122–1134.
   PubMed Web of Science ®Google Scholar
• Kusawake, T., et al., 2017. Pharmacokinetic evaluation of the interactions of amenamevir (ASP2151) with ketoconazole, rifampicin, midazolam, and warfarin in healthy adults. Advances in therapy, 34 (11), 2466–2480.
   PubMed Web of Science ®Google Scholar
• Lam, Y.W., et al., 2003. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. Journal of clinical pharmacology, 43 (11), 1274–1282.
   PubMed Web of Science ®Google Scholar
• Link, B., et al., 2008. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. British journal of clinical pharmacology, 66 (4), 473–484.
   PubMed Web of Science ®Google Scholar
• Martínez, C., et al., 1999. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clinical pharmacology & therapeutics, 65 (4), 369–376.
   PubMed Web of Science ®Google Scholar
• May, D.C., et al., 1982. Effects of cimetidine on caffeine disposition in smokers and nonsmokers. Clinical pharmacology and therapeutics, 31 (5), 656–661.
   PubMed Web of Science ®Google Scholar
• Morcos, P.N., et al., 2017. Clinical drug-drug interactions through cytochrome P450 3A (CYP3A) for the selective ALK inhibitor alectinib. Clinical pharmacology in drug development, 6 (3), 280–291.
   PubMed Web of Science ®Google Scholar
• Moscovitz, J.E., et al., 2018. Induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999 is mediated by the pregnane X receptor. Xenobiotica; the fate of foreign compounds in biological systems, 48 (7), 647–655.
   PubMed Web of Science ®Google Scholar
• Mouly, S., et al., 2015. Drug-food interactions in internal medicine: What physicians should know? La Revue de Medecine Interne, 36 (8), 530–539.
   PubMed Web of Science ®Google Scholar
• Neuvonen, P.J., Kantola, T., and Kivistö, K.T., 1998. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clinical pharmacology & therapeutics, 63 (3), 332–341.
   PubMed Web of Science ®Google Scholar
• Ouwerkerk-Mahadevan, S., et al., 2016. Drug-drug interactions with the NS3/4A protease inhibitor simeprevir. Clinical pharmacokinetics, 55 (2), 197–208.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont, T., et al., 2017. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clinical pharmacology and therapeutics, 101 (4), 519–530.
   PubMed Web of Science ®Google Scholar
• Ryu, J.Y., et al., 2007. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clinical pharmacology and therapeutics, 82 (5), 531–540.
   PubMed Web of Science ®Google Scholar
• Sager, J.E., et al., 2015. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug metabolism and disposition: the biological fate of chemicals, 43 (11), 1823–1837.
   PubMed Web of Science ®Google Scholar
• Salonen, M., et al., 1986. Importance of the interaction of midazolam and cimetidine. Acta pharmacologica et toxicologica, 58 (2), 91–95.
   PubMedGoogle Scholar
• Streetman, D.S., et al., 2000. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clinical pharmacology and therapeutics, 68 (4), 375–383.
   PubMed Web of Science ®Google Scholar
• Tahara, H., Watanabe, M., and Hasegawa, M., 2019. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys. Biopharmaceutics & drug disposition, 40 (2), 81–93.
   PubMed Web of Science ®Google Scholar
• Tanaka, S., et al., 2014. Simultaneous LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 substrate drugs and their metabolites. Biological & pharmaceutical bulletin, 37 (1), 18–25.
   PubMed Web of Science ®Google Scholar
• The Ministry of Health, Labour and Welfare, 2018. Guideline on drug interaction for drug development and appropriate provision of information. Available from: https://www.pmda.go.jp/files/000228122.pdf [Accessed 1 December 2019].
   Google Scholar
• Treijtel, N., et al., 2019. A cocktail interaction study evaluating the drug-drug interaction potential of the perpetrator drug ASP8477 at multiple ascending dose levels. Clinical pharmacology in drug development, 8 (4), 529–540.
   PubMed Web of Science ®Google Scholar
• Trueck, C., Hsin, C.H., et al., 2019. A clinical drug-drug interaction study assessing a novel drug transporter phenotyping cocktail with adefovir, sitagliptin, metformin, pitavastatin, and digoxin. Clinical pharmacology & therapeutics, 106 (6), 1398–1407.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2017. Clinical drug interaction studies - study design, data analysis, and clinical implications guidance for industry. Available from: https://www.fda.gov/media/82734/download. [Accessed 1 December 2019].
   Google Scholar
• van Dyk, M., et al., 2018. Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries. European journal of clinical pharmacology, 74 (7), 913–920.
   PubMed Web of Science ®Google Scholar
• Wang, X., et al., 2018. Effects of rolapitant administered intravenously on the pharmacokinetics of a modified cooperstown cocktail (midazolam, omeprazole, warfarin, caffeine, and dextromethorphan) in healthy subjects. Journal of clinical pharmacology, 58 (8), 1074–1083.
   PubMed Web of Science ®Google Scholar
• Williams, D., and Feely, J., 2002. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clinical pharmacokinetics, 41 (5), 343–370.
   PubMed Web of Science ®Google Scholar
• Williamson, K.M., et al., 1998. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clinical pharmacology & therapeutics, 63 (3), 316–323.
   PubMed Web of Science ®Google Scholar
• Yamashita, F., 2016. Modeling and simulation of pharmacokinetic drug-drug interaction caused by induction of metabolic enzymes. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica, 147 (2), 95–100.
   PubMedGoogle Scholar
• Yasui-Furukori, N., et al., 2004. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. British journal of clinical pharmacology, 57 (4), 487–494.
   PubMed Web of Science ®Google Scholar